Navigation Links
Unstable chromosomes linked to less favorable response to RT and surgery in prostate cancer patients
Date:9/25/2013

Atlanta, September 25, 2013 -- Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image-guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study results indicate that patients who have abnormal levels of breaks at common fragile sites (CFSs), sites within the chromosomes that are sensitive to DNA damage, are more likely to have their cancer to return -- treatment failure. These CFS break abnormalities are usually associated with instability of the cell's DNA, a phenomenon that is particularly associated with cancer.

In this study, researchers assessed the outcomes of 280 prostate cancer (Cap) patients, and reviewed the DNA "fingerprints" of each patient's tumor (using the patient's initial diagnostic core biopsy) to determine if gene copy number alterations (CNAs), or breaks in CFSs, were related to a less positive response to treatment. Two groups were analyzed: 126 localized intermediate risk CaP patients who had received image-guided radiation therapy (IGRT) treatments, with a mean dose of 74.6 Gy; and 154 localized intermediate and high risk CaP patients who had undergone radical prostatectomy (RP), which is the surgical removal of the entire prostate gland.

Utilizing an array comparative genomic hybridization (aCGH), DNA from frozen needle biopsies of the RT patients was analyzed for 13 previously characterized CFSs: FRA2G, FRA3B, FRA4F, FRA6E, FRA6F, FRA7E, FRA7G, FRA7H, FRA7I, FRA7K, FRA8C, FRA9E, FRA16D. The effect of having at least one CNA in any CFS was assessed using the Kaplan-Meier method and Cox proportional hazard models.

The data revealed a pattern in which the patients who failed treatment had abnormal levels of CNAs at CFSs. In the IGRT group, CNAs in CFSs occurred frequently, with 80 of the patients (64 percent) having a CNA in one or more CFS locations (median was 1, and the range was 0 10).

Each patient's biochemical relapse-free rate (bRFR) was gauged, because if a patient relapses biochemically, his prostate specific antigen level has risen significantly and this is a reasonable indicator that the cancer has recurred. Thus, a high bRFR is desirable. On univariate analysis, patients with a CNA in at least one CFS showed a decreased 5-year bRFR (64 percent), compared with the bRFR of patients without genetic alteration in CFSs (90 percent; HR = 2.13, 95% CI: 1.17-3.86, p = 0.011). After adjusting for clinical factors in a multivariate model, a CNA in a CFS was determined to be a significant independent predictor of decreased response to radiation therapy and higher incidence of recurring cancer. (HR = 2.94, 95% CI: 1.51-5.75, P = 0.0016).

The results of the 154 patients in the RP group were compiled using the publically available Memorial Sloan-Kettering Cancer Center (MSKCC) aCGH database of patients. CNAs in CFSs were also frequent in the RP group, with 81 patients (53 percent) having a CNA in one or more location (median was 1, and the range was 0 6). These results also correlated to decreased 5-year bRFR rates of 68 percent, compared to 82 percent for RP patients without genetic alterations in CFSs (HR = 1.79). Despite this strong trend, after adjusting for clinical factors in a multivariate model, a CNA in a CFS was not a statistically significant predictor of cancer recurrence (HR = 1.52, 95% CI: 0.77-3.02, P = 0.23).

"We thought that patients who have CFS breaks might be more sensitive to radiation therapy-induced DNA damage," said the lead author of the study, Robert G. Bristow, MD, PhD, a Professor within the radiation oncology and medical biophysics departments at the University of Toronto; and a Clinician-Scientist at the Princess Margaret Cancer Centre in Toronto. "We now think that the CFS breaks are a signal that the cancer cell has acquired numerous genetic changes that lead to more aggressive cancer cells that can spread early and outside the prostate gland. Our data suggest that the patients failing treatment are due to early metastatic (distant spread) disease. If we validate this study in similar, but larger groups of patients, we can develop a test based for CFS breaks; the results would allow us to place patients in one of two categories: those whose tumors do not have CFS breaks and who would likely do well with local treatment alone (e.g. radiotherapy or surgery); and, those patients whose tumors do have CFS breaks and would need a more complex treatment protocol, in addition to RT or surgery, to combat distant spread."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Skechers Fracture Lawsuit Filed on Behalf of an Arizona Woman Who Sustained Multiple Arm Fractures Allegedly Due to Unstable Shape-Ups, by Wright & Schulte
2. Dual systems key to keeping chromosomes intact
3. Scientists discover how chromosomes keep their loose ends loose
4. Caloric restriction has a protective effect on chromosomes
5. Warwick scientists uncover how checkpoint proteins bind chromosomes
6. HPV Linked to Growing Number of Young Adults with Oropharyngeal Cancer
7. HPV linked to growing number of young adults with oropharyngeal cancer
8. Casey Gollan’s LinkedIn Tips for Entrepreneurs
9. Fragile X syndrome protein linked to breast cancer progression
10. Cold sore linked to mutation in gene, study suggests
11. Study suggests antioxidant treatment may help NF1-linked behavioral issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... , ... SC&H Group, a leading audit, tax, and consulting firm, announced that ... Services practice . Rossi is the third technology consulting leader to join SC&H Group’s ... and the practice continues to expand.     , Bringing more than 25 years of business ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians ... Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, ... the announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra ...
(Date:1/17/2017)... ... ... people make New Year’s resolutions or renew their commitment to better health with the start ... who want to kick off 2017 with better smiles. Dr. Mondavi is offering several promotions ... include: , , A new patient package for just $49, which ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide comfort and fuel ... the fast-casual category, announces a hearty and wholesome Winter Menu. Starting today, guests ... Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken & Sausage ...
(Date:1/16/2017)... , ... January 16, 2017 , ... Gym Source, America’s ... a new showroom in East Hanover, New Jersey. , “We are elated to be ... new innovative in-store concept is designed to give clients a seamless and motivating shopping ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... System Market 2016-2020" report to their offering. ... The global artificial pancreas devices ... period 2016-2020. Global Artificial Pancreas Devices System Market 2016-2020, ... from industry experts. The report covers the market landscape and its ...
(Date:1/17/2017)... Jan. 17, 2017 Paragon Bioservices received a ... development services for a variety of National ... medical product development activities. The IDIQ mechanism will ... for task order awards up to $159 million. ... manufacturing and process development of biopharmaceuticals, is one ...
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... has been enrolled in a Phase 3 clinical trial ... supportive care (BSC) in the prevention of hepatic veno-occlusive ... stem cell transplant (HSCT) who are at high risk ... defibrotide clinical trial will be conducted across approximately 100 ...
Breaking Medicine Technology: